Bupleurum Injection Veterinary Grade API is a standardised Radix Bupleuri extract stream controlled for downstream conversion into tablets, injections, capsules, powders, granules, premix, and solutions. The active fraction is a multi-component triterpene saponin complex in which saikosaponin A, B2, C, and D are quantified by HPLC-ELSD or low-wavelength UV detection against a qualified reference standard. Injection-grade batches carry additional release criteria for bacterial endotoxin, sub-visible particulate burden, water content, and residual solvent profile because parenteral processing tolerates less physicochemical variability than non-sterile oral routes. Dry-route batches are milled and flow-conditioned, but the injection-grade designation is not automatically transferable to non-sterile dosage forms unless the full injectable specification is met. The application scenarios below are restricted to legally and technically valid veterinary formulation routes: injectable antipyretic solutions, oral water-soluble powders, medicated feed premixes, companion-animal tablets, hard-shell capsules, and oral granules. Each route carries different microbial limits, manufacturing equipment constraints, and pH-dependent stability boundaries.

Sterile Injectable Aqueous Solutions: Heat-Labile Glycosides and the Aseptic Filtration Boundary

Formulation for parenteral use is initiated by dissolving the extract in Water for Injection at 35–40 °C under vacuum-assisted recirculation. A starting charge of 20 g/L (2.0% w/v) is adjusted after HPLC-ELSD assay so that the labelled marker is expressed as saikosaponin A content rather than raw herb equivalent; for poultry protocols, the working solution may be diluted before filling to 1.0% w/v. The solution pH is maintained at 5.5–6.5 with a citrate buffer system because triterpene glycoside moieties undergo accelerated hydrolysis below pH 3.0 and foaming increases above pH 8.0. Clarification is performed through a 0.45 µm PVDF membrane followed by sterilising-grade filtration through a 0.22 µm PVDF membrane; terminal steam sterilisation at 121 °C is avoided because published stability data for saikosaponin-rich aqueous extracts under saturated steam are negative. The solution is filled under nitrogen overlay into amber type I glass vials of 10 mL, 20 mL, and 50 mL. Compliance is demonstrated by USP <71> sterility by membrane filtration, USP <85> bacterial endotoxin limits calculated from the maximum dose and typically controlled at ≤0.5 EU/mg or stricter, USP <788> particulate matter, USP <467> residual solvents, ICH Q3D elemental impurities, and VICH GL18 residual solvent classification. Herbal identity is controlled against the relevant monograph of the Chinese Veterinary Pharmacopoeia 2020 edition for Radix Bupleuri. Production-scale failure modes include proteinaceous foam that traps extract solids on the first filter, vial headspace oxygen causing pH drift, and sub-visible precipitation when the solution is compounded above 40 °C then cooled too rapidly. The terminal dosage form is a sterile injectable solution intended for porcine, bovine, and poultry antipyretic and anti-inflammatory protocols.

In poultry drinking-water programmes, a water-soluble oral powder is prepared from the same standardised extract to avoid injection-related handling in large flocks. The powder is formulated as a freely dispersible mixture of spray-dried extract on maltodextrin and silicon dioxide, with the addition ratio set so that a 100 g sachet yields a 1:1,000 stock solution carrying 0.5–1.0 g extract per litre of finished drinking water. Oral powders are not required to meet sterility; instead they must satisfy USP <61> microbial enumeration and USP <62> specified microorganism limits, with loss on drying controlled at NMT 5.0% because residual moisture above this threshold accelerates caking under high-humidity poultry-house conditions. The production sequence uses a 500 L ribbon blender at 70% usable capacity, with the extract pre-sieved through a 0.5 mm screen to reduce wetting lag; mixing continues for 15 min after the final minor-component addition, and a 1 kg composite sample is collected every 20 min for marker assay. Sachet filling is performed on a form-fill-seal line at 23–25 °C and RH <45%. The terminal products are 100 g and 500 g printed sachets for oral administration in broilers, layers, and turkey poults. Chlorinated drinking water should be tested as an incompatibility risk because free chlorine above 2 ppm may oxidise the triterpene backbone and reduce saikosaponin assay recovery.

Why pH and Carrier Loading Dictate Premix Stability in Medicated Feed

In feed premix manufacturing, the extract is not simply blended into feed; it is first dispersed on a high-surface-area carrier to stabilise the saponin fraction and prevent segregation. A typical premix carries 5–20% w/w standardised extract on a 1:1 silicon dioxide–calcium carbonate carrier, with final addition into complete feed ranging from 0.5–2 kg premix per tonne, corresponding to 50–400 g extract per tonne of finished feed. The regulatory route in the European Union places the material under Regulation (EU) 2019/6 for veterinary medicinal products and Regulation (EU) 2019/4 for medicated feed where a veterinary prescription is required; if the intended market treats the product as a feed additive, Regulation (EC) 1831/2003 and Regulation (EC) 183/2005 apply, and the national registration status must be confirmed before batch import or sale. The production sequence includes a 250 L paddle mixer for extract-carrier dispersion at 45 rpm, followed by stepwise dilution with ground limestone and a final ribbon-blender run at 70% fill. Demixing is observed when the extract D90 exceeds 250 µm while the carrier D50 is 100 µm; therefore the extract is milled to D90 180 µm before dispersion. Moisture content must remain below 6.0%, and the premix must not be combined with acidifier packages that lower local pH below 4.5 because saikosaponin glycosides undergo acid-catalysed cleavage. The terminal products are 1 kg, 5 kg, and 25 kg multiwall paper bags with inner polyethylene liners for swine and poultry feed mills. Marker recovery in finished feed matrices is ordinarily more variable than recovery in aqueous solution because of interference from phytase, mineral supplements, and corn–soy matrix compounds; a spiked feed recovery study is therefore required before setting the label claim.

When Bupleurum Extract Is Compressed Into Companion-Animal Hepatoprotective Tablets

For companion-animal tablets, the extract is processed by wet granulation rather than direct compression because spray-dried Radix Bupleuri powder exhibits high hygroscopicity and poor compactibility. The standardised extract is charged at 20–40% w/w of the core granulation; microcrystalline cellulose and lactose monohydrate act as diluents, croscarmellose sodium is used at 2–4% w/w as disintegrant, and povidone K30 at 2.5% w/w is added as a binder solution in purified water. Granulation is performed in a high-shear mixer with impeller speed 300 rpm and chopper speed 1,500 rpm; the wet mass is dried in a fluid-bed dryer with inlet air at 55–60 °C until loss on drying is NMT 3.0%. The dried granulate is milled through a 0.8 mm screen and compressed on a rotary tablet press with pre-compression force 6 kN and main compression force 12–15 kN. Finished tablets of 200 mg and 500 mg core weight are film-coated with a hydroxypropyl methylcellulose system. Compliance includes USP <905> uniformity of dosage units, USP <701> disintegration, USP <711> dissolution, and USP <561> botanical identity. Published comparative dissolution data for saikosaponin A from these tablets in fasted canine gastric fluid are limited; a screening method using USP apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid at 37 °C is therefore qualified against the reference product during development. The major production risk is tablet surface tacking when the granulate is stored above RH 50% before compression; sustained-release or enteric coating is not recommended because the acid-labile saponin fraction would require a protective subcoat and may increase assay variance. The terminal dosage form is a film-coated tablet for dogs and cats in hepatoprotective maintenance protocols.

Hard-shell capsules containing the dried extract are manufactured for small-animal and equine maintenance protocols where dose flexibility is required. The capsule fill is prepared at an extract-to-excipient dilution of 1:2 to 1:4; a representative size-0 capsule formula contains 100 mg standardised extract, 180 mg lactose monohydrate, 18 mg croscarmellose sodium, and 2 mg colloidal silicon dioxide, yielding a total fill mass of 300 mg. The extract is pre-dried at 40 °C under vacuum to NMT 3.0% moisture and milled through a 0.5 mm screen before blending in a 100 L V-blender at 15 rpm for 20 min. Encapsulation is conducted at 23 °C and RH 35–45% on an intermittent-motion capsule filler; HPMC or gelatin capsule shells must have a moisture specification below 13.0% because the extract can transfer moisture and cause shell softening. The terminal packages are 60-count and 120-count white HDPE bottles containing desiccant. Compliance requirements follow USP <905> for content uniformity and USP <711> for dissolution, with microbial limits per USP <61> and USP <62>. The main process failure is electrostatic segregation of saponin-rich fines, which is controlled by colloidal silicon dioxide and by keeping the V-blender shell grounded. Capsules are selected over tablets when the target species rejects coated tablets or when the prescribed dose must be adjusted within a therapeutic protocol.

Granular presentations for oral drenching, top-dressing, and in-feed administration use an extrusion-spheronisation process that converts the hygroscopic extract into a denser, low-dust granule. The granule charge includes 10–30% w/w standardised extract, 2–5% w/w povidone K30 binder, 0.5% w/w colloidal silicon dioxide, and lactose monohydrate as filler. Purified water is added under high-shear mixing until the end-point torque corresponds to a wet mass with 42–48% w/w moisture. The wet mass is extruded through a twin-screw extruder with an L/D ratio of 24:1 and a 0.8 mm die plate at 120 rpm; spheronisation is carried out at 600 rpm for 4–6 min on a plate temperature-controlled to 25 °C. Drying in a fluid-bed dryer with inlet air at 50 °C reduces moisture to NMT 4.0%. The final granule fraction is sieved to 0.8–1.4 mm, with fines recycled into the next batch. Compliance is non-sterile oral: USP <61> and USP <62> microbial limits, with process validation conducted under veterinary GMP and analytical methods validated according to ICH Q2(R1). The terminal packages are 100 g and 250 g HDPE jars. Granules are used for calves, foals, and small ruminants where drench-gun administration or top-dressed feed avoids the dusting risk of the powder. Storage stability is governed by moisture ingress; desiccant capacity must be calculated for a 24-month shelf life in high-humidity climates.